RCLS and the detection of Gastric Cancer
Randox are producing high quality IVD products based the 36 years’ expertise and knowledge they have built. RCLS specialises in biomarker and multiplex testing to provide full laboratory services. Currently, there are four laboratories across the UK located in Liverpool, London, Holywood and the Randox Science Park in Antrim. Overall, the RCLS team aim to save your laboratory time and money.
The NHS states that every year, over 6,000 people are diagnosed with Gastric Cancer in the UK 1. Gastric Cancer is the world’s 5th most common disease which cancer cells form in the lining of the stomach. There are many symptoms of stomach cancer including indigestion, heartburn, trapped wind and many other syndromes.
However, often this type of cancer is diagnosed at an advanced stage when the treatment is less effective. Matt Atherton emphasises the importance of diagnosing stomach cancer early as the overall patient experience would be easier and more effective. 2 Dr Shekhar Patil explained that as a result, early diagnoses lead to increased survival rates 3. Identifying cancer at an early stage also benefits the patient financially impact as less expensive treatment can be carried out. The World Health Organisation4 has said that, overall, detecting cancer early is more effective, less complex and less expensive.
Randox Clinical Laboratory Services (RCLS) offers a Gastro Panel Array which encompasses two quantitative arrays, a H. pylori assay for the detection of antibodies produced in response to a H. pylori infection, a common cause of gastric cancer as well as a 3plex GastroPanel assay, for the detection of pepsinogen I (PGI), pepsinogen II (PGII) and gastrin 17 (G17).
Our Gastro Panel Array offers patients a comprehensive patient profile of gastric health through a single blood sample and can increase survival rates! RCLS offers accurate, rapid and precise results while improving patient care.
If you would like more information on RCLS please contact firstname.lastname@example.org
Drug residues in milk present major concern for farmers, dairy processors, cheese manufacturers, authorities and consumers due to the potential public health and industrial implications. Through the potential inappropriate antimicrobial use in animals producing product for human consumption, antibiotic-resistant organisms can enter the food supply or can spread to various components of the ecosystem. For consumer protection, regulatory limits have been set for the majority of compounds.
Randox Food Diagnostics provides screening technology to monitor the levels of these potentially harmful compounds including the Infiniplex for Milk Array available on the Evidence Investigator and Evidence Multistat analysers.
Using the Randox Food technology the user can identify 130 analytes from a 200µl sample of raw milk and follows this simple process to results:
- Pipette the sample directly onto the MultiSTAT biochip
- Insert into the Evidence MultiSTAT
- Press Play and follow the on-screen prompts
- Results appear on screen in under 20 minutes
Developed to provide an easy to use option for the user, the Infiniplex Array for Multistat can be used by anyone to ensure rapid on-site testing within the dairy industry.
The InfiniPlex test menu is 98% compliant with EU regulations and screens for additional contaminants including; antiparasitic, anti-inflammatories, non-steroidal and unauthorised substances from one sample of raw milk, creating a better end product for the processor and end user.
To find out more about InfiniPlex contact email@example.com
Chronic Kidney Disease (CKD) is a long term condition which involves the progressive loss of kidney function a late diagnosis can result in end stage renal disease requiring kidney dialysis or transplantation. Typically, CKD is result of a combination of other conditions which puts a strain on the kidneys, these conditions can include high blood pressure, diabetes and high cholesterol amongst many other ailments.1
Randox Biosciences are continually researching and developing new tests, targeting various health concerns around the world to improve diagnostics and health worldwide. Recently, our dedicated scientists have developed a new test, utilising our proprietary Biochip Array Technology (BAT) that simultaneously and quantitatively detects multiple early biomarkers associated with kidney damage allowing for earlier intervention and treatment, preventing further kidney damage.
We offer two multiplex Chronic Kidney Arrays as shown below:
Early detection provides those diagnosed with the opportunity to alter their lifestyle in order to improve their kidney and overall health, whether that is through the reduction of salt in their diet, increased physical activity and alcohol limitation.
To find out more about the Chronic Kidney Disease Arrays offered by Biosciences email firstname.lastname@example.org
1 NHS – https://www.nhs.uk/conditions/kidney-disease/